Insiders AnaptysBio, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-13 pm EDT			5-day change	1st Jan Change
24.25 ^USD	+0.62%		+1.42%	+13.21%

May. 09	AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
May. 09	Anaptys Announces Positive Top-Line Gemini-2 Phase 3 Clinical Trial Results of imsidolimab (IL-36R) in Generalized Pustular Psoriasis	CI

AnaptysBio Names John Orwin as Board Chairman	23-09-18	MT
AnaptysBio, Inc. Announces Board Changes	23-09-18	CI
AnaptysBio, Inc. Announces Board Changes	23-04-06	CI
AnaptysBio Taps Former Mirati Therapeutics' COO as Interim CEO	22-03-21	MT
AnaptysBio, Inc. Announces Management Changes	22-03-21	CI
AnaptysBio, Inc. Announces Executive Changes	22-03-21	CI
Insider Sell: Anaptysbio	21-12-23	MT
Hexima Names New Chief Development Officer	21-12-01	MT
AnaptysBio, Inc. Announces Appointment of Daniel Faga to Board of Directors	21-11-29	CI
Insider Sell: Anaptysbio	21-11-03	MT
Insider Trends: Insider Buying Continued with Purchase of AnaptysBio Stock	21-05-04	MT
Insider Trends: Insider Purchase Adds to AnaptysBio Positive Trend	21-04-27	MT
Anaptysbio, Inc. Appoints Oleg Nodelman as A Class I Director on Its Board of Directors	21-04-12	CI
AnaptysBio, Inc. Announces Board Changes	21-01-19	CI
AnaptysBio, Inc. Appoints Paul F. Lizzul as Chief Medical Officer	20-07-31	CI
Anaptysbio, Inc. Appoints Eric Loumeau as Chief Operating Officer	20-07-15	CI
AnaptysBio, Inc. Announces Executive Changes	20-03-09	CI
AnaptysBio, Inc. Appoints Laura Hamill as Class II Director	19-09-25	CI
Nicholas B. Lydon, Class II Director, Not to Stand for Re-Election at AGM of AnaptysBio, Inc	19-04-26	CI
AnaptysBio, Inc. Announces Board and Audit Committee Changes	18-03-20	CI

No results for this search